Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esketamine + magnesium sulfate
- Development stage
- Approved
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
esketamine + magnesium sulfate is a combination therapy being investigated for the prevention and treatment of postoperative fatigue syndrome (POFS), particularly in patients undergoing laparoscopic cholecystectomy. Esketamine, the S-enantiomer of ketamine, acts as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, which helps mitigate central sensitization and neuroinflammation by blocking microglial IL-6 release and enhancing neuroplasticity via BDNF/TrkB upregulation. Magnesium sulfate serves as a physiological NMDA receptor antagonist and a blocker of voltage-gated calcium channels, providing complementary effects by reducing calcium overload and supporting cellular energy metabolism as an ATPase cofactor. This combination aims to address both the central neurological and peripheral metabolic components of postoperative fatigue to accelerate rehabilitation.
- Other names
- Esketamine and Magnesium sulfate
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)CaV (Voltage-gated calcium channel protein complex)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on esketamine + magnesium sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esketamine + magnesium sulfate.